Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration (FDA) clearance to advance its lead multiple sclerosis (MS) candidate, Lucid-MS (Lucid-21-302), into Phase 2 clinical development. The approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as quickly as possible.
Lucid-MS is a first-in-class candidate that aims to provide neuroprotection by inhibiting demyelination, the process by which the protective myelin sheath around nerve fibers is damaged. This mechanism differentiates it from existing MS therapies that primarily focus on modulating the immune system. The drug targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown, offering a potential disease-modifying approach that could address the underlying pathophysiology of MS. Additionally, prior Phase 1 trials in healthy participants showed that Lucid-MS was well tolerated and exhibited a favorable safety profile.
The clearance to proceed to Phase 2 is a significant milestone for Quantum BioPharma, as it advances the company's lead asset into later-stage development. The company reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which provides financial runway to support the upcoming trial. This development is particularly important given the unmet medical need in MS, where current treatments often fail to halt disease progression or repair existing damage. If successful, Lucid-MS could offer a novel therapeutic option that not only slows disease but potentially restores neurological function.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. Beyond its MS program, Quantum has also developed UNBUZZD, a product aimed at alcohol misuse, and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets the over-the-counter version. The company also earns royalty payments from Unbuzzd sales, providing additional potential revenue streams.
The FDA's clearance of the IND application for Lucid-MS is a critical step forward in the clinical development of a potentially transformative therapy for multiple sclerosis. As the company moves into Phase 2, the focus will be on demonstrating clinical benefit in patients, which could ultimately lead to a new treatment option that addresses the root cause of the disease. For more information on the full press release, visit https://ibn.fm/HyWYH.
